Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emraclidine PK Interaction with Itraconazole, Carbamazepine, and Metformin
NCT05965219Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Aug 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emraclidine in schizophrenia (3 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve from Time Zero to Last Specified Sampling Time and 1 more. Started Aug 2023; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05965219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965219.